- Open Access
METTL3 suppresses anlotinib sensitivity by regulating m6A modification of FGFR3 in oral squamous cell carcinoma
Cancer Cell International volume 22, Article number: 295 (2022)
N6-methyladenosine (m6A) is an abundant nucleotide modification in mRNA, but there were few studies on its role in cancer drug sensitivity and resistance. Anlotinib has been proved to have effective antitumor effects in oral squamous cell carcinoma (OSCC) in our previous study. Here, we sought to investigate the treatment target of anlotinib and the function and mechanisms of m6A modification in regulating anlotinib effect in OSCC.
Anlotinib treatment in a dose-dependent manner, western blotting, qRT-PCR and cell lost-of-function assays were used to study the treatment target of anlotinib in OSCC. RNA m6A dot blot assays, the m6A MeRIP-seq and MeRIP-qPCR, RNA and protein stability assays were used to explore the m6A modification of the treatment target of anlotinib. Cell lost-of-function assays after METTL3 depletion were conducted to investigate the effect of m6A modification level on the therapeutic effect of anlotinib in OSCC. Patient-derived tumor xenograft (PDX) models and immunohistochemistry staining were performed to study the relationship of METTL3 and antitumor sensitivity of anlotinib in vivo.
Anlotinib targeted FGFR3 in the treatment of OSCC and inhibited tumor cell proliferation and promoted apoptosis by inactivating the FGFR3/AKT/mTOR signaling pathway. METTL3 was identified to target and modify FGFR3 m6A methylation and then decrease the stability of mRNA. METTL3 expression level was related to the anlotinib sensitivity in OSCC cells in vitro and METTL3 knockdown promoted anlotinib sensitivity of OSCC cells by inhibiting the FGFR3 expression. PDX models samples furthermore showed that METTL3 and FGFR3 levels were tightly correlated with the anlotinib efficacy in OSCC.
In summary, our work revealed that FGFR3 was served as the treatment target of anlotinib and METTL3-mediated FGFR3 m6A modification played a critical function in the anlotinib sensitivity in OSCC.
Oral squamous cell carcinoma (OSCC) is the most common malignant tumor of the oral cavity and is prone to local recurrence and metastasis [1, 2]. To date, palliative drug therapy is an important treatment for patients with advanced, recurrent and metastatic OSCC , including traditional cytotoxic chemotherapy (Cisplatin, 5-FU and Paclitaxel), molecular targeted therapy (Cetuximab, Nimotuzumab and Sorafenib) and immunotherapy (Pembrolizumab and Nivolumab) [3,4,5,6]. However, tumors heterogeneity and the existence of drug resistance had been proved to limit the therapeutic effect of drug therapy. Thus, elucidation of mechanisms underlying the sensitivity and resistance to these drugs is needed to improve response in OSCC patients [6,7,8].
Anlotinib is a multi-target tyrosine kinase inhibitor (TKI) that can efficiently and selectively inhibit tyrosine kinase activity and then inhibit phosphorylation of downstream related proteins [9,10,11], such as vascular endothelial cell growth factor receptor 1, 2, 3 (VEGFR1, VEGFR2, VEGFR3), stem cell growth factor receptor (c-Kit), platelet-derived growth factor receptor beta (PDGFRβ) and fibroblast growth factor receptor (FGFR) 1–4. Multiple studies have shown that anlotinib has an anti-angiogenic and direct killing effect on a variety of tumor cells [11,12,13,14,15]. Our previous study also found that anlotinib monotherapy exerted favorable anticancer activity and manageable toxicities in patients with recurrent and metastatic OSCC . However, the reported anlotinib insensitiveness and resistance impeded its anti-tumor effectiveness [17, 18].
Cancer therapeutic sensitivity is an intricated phenomenon affected by multiple mechanisms [19,20,21,22], including altered expression of drug influx/efflux transporters, the altered role of DNA repair and impairment of apoptosis, and altered epigenomics influencing upstream or downstream effectors. As a dynamic and reversible internal modification of RNA, N6-methyladenosine (m6A) methylation has been frequently reported promoting the tumor growth and metastasis in human cancers [23,24,25,26,27,28]. Targeting key regulators of m6A modification may be a potential cancer treatment target . We previously studied that RNA m6A modification enzyme methyltransferase-like 3 (METTL3) promoted OSCC proliferation and metastasis through B cell-specific Moloney murine leukemia virus insertion site 1 (BMI1) m6A methylation . To date, many studies have found that METTL3 regulated drug resistance in human cancers. Jin et al.  found that METTL3 induced RNA m6A modification by upregulating ATP binding cassette subfamily G member 2 (ABCG2) transcripts and regulated ABCG2-dependent multidrug resistance in non-small cell lung cancer. Uddin et al.  found that METTL3 depletion suppressed the expression of mutant p53 and sensitized colorectal cells to doxorubicin. METTL3 upregulates the expression of ubiquitin-conjugating enzyme E2B (UBE2B), a critical DNA damage repair enzyme, leading to drug resistance to 5-FU, cisplatin and gemcitabine [32, 33].
To date, the exact target and the underline mechanism of anlotinib in OSCC have not been sufficiently elucidated. In this study, we aimed to explore the exact target of anlotinib in OSCC and explore the role of m6A modification in anlotinib sensitivity of OSCC. Functional studies revealed that anlotinib targeted FGFR3 in the treatment of OSCC in vitro. m6A-RNA immunoprecipitation and sequencing (MeRIP-seq), MeRIP-qPCR, and RNA and protein stability assays revealed that METTL3 could modify FGFR3 mRNA m6A modification and decrease FGFR3 mRNA stability. METTL3 knockdown promoted anlotinib sensitivity of OSCC cells by increasing FGFR3 expression, and the expression level of METTL3 and FGFR3 was tightly correlated with the efficacy of anlotinib in OSCC.
Cell culture and transfection
Human normal oral epithelial keratinocytes (HOK) cells were purchased from ScienCell. Human umbilical cord veins cells (HUVECs), SCC9, SCC15, SCC25 and UM1 were purchased from ATCC. The OSCC cell lines were cultured in Dulbecco’s modified Eagle’s medium/F12 (Gibco, New York, USA) with 10% fetal bovine serum (FBS; Gibco) and 1% penicillin–streptomycin, incubated in 5% CO2 at 37℃. Anlotinib dihydrochloride was kindly provided by the Chia Tai Tianqing Pharmaceutical Group Co. Ltd. (Nanjing, China).
Lentivirus vectors containing METTL3 short hairpin RNA (shRNA) were purchased from OBiOc (Shanghai, China). Small interfering RNAs (siRNAs) (RiboBio, Guangzhou, China) targeting FGFR3 were designed to knockdown FGFR3 in OSCC. The indicated two shRNA and three siFGFR3 sequences are listed in Additional file 5: Table S1.
The cells (5 × 103) were planted in 96-well plates and then treated with specified concentrations of anlotinib for 24 h. Cell viability was performed using Cell Counting Kit-8 (CCK-8) (Dojindo, Japan) following the instructions. The formula was ([ODt—ODb] / [ODc—ODb]) × 100% (OD: optical density, t: treated sample, c: control sample, b: blank sample) . Then IC50 values were counted with GraphPad Prism software (San Diego, CA, USA).
Cell apoptosis assay
Cell apoptosis assays was performed with Annexin V-FITC/PI Apoptosis Assay Kit (MultiSciences, Hangzhou, China) according to the manufacturer’s protocol. After treatment with anlotinib for 24 h, flow cytometric analysis of fixed and stained cells was performed using CytoFLEX (Beckman Coulter, Brea, USA). Data analysis was performed using Flowjo software of 7.6 version (FLOWJO LLC, Ashland, USA).
Total protein was lysed with proteinase inhibitor cocktail and radioimmunoprecipitation assay (RIPA) buffer with and conditionally adding phosphatase inhibitors (Sangon Biotech, Shanghai, China). The protein samples were then mixed with 5 × loading buffer, then denatured at 95℃ for 5 min, and electrotransferred to polyvinylidene fluoride (PVDF) membrane by 10% sodium dodecyl sulfate–polyacrylamide gel electrophoresis (SDS-PAGE). After blocking with 5% skim milk, the membrane was incubated in the primary antibody overnight at 4 °C, and then the secondary antibody diluted in Tris-buffered saline with Tween 20 (TBST) was used. Then, the protein-antibody complexes were detected using the enhanced chemiluminescence (ECL) on the Tanon 5200 Multi intelligent imaging system. The primary antibody used in this study are shown as below: VEGFR1 (Affinity, AF6204), VEGFR2 (Cell signaling Technology, 9698), VEGFR3 (Affinity, AF4201), FGFR1 (Signalway Antibody, 49,175), FGFR2 (Abcam, ab109372), FGFR3 (Abcam, ab133644), FGFR4 (Abcam, ab119378), c-Kit (Bioworld Technology, BS2433), PDGFRβ (Bioworld Technology, BS1764), GAPDH (Proteintech, 60,004), p-FGFR3 (Abcam, ab155960), AKT (Affinity, AF6261), p-AKT (Affinity, AF0016), mTOR (Affinity, AF6308), p-Mtor (Affinity, AF3308), BCL2 (Proteintech, 12,789–1-AP), BAX (Abcam, ab32503), METTL3 (Proteintech, 15,073–1-AP).
Quantitative real-time PCR (qRT-PCR)
Total RNAs were extracted with TRIzol™ Reagent (Invitrogen, Carlsbad, USA) according to the manufacturer’s instruction. Reverse-transcription was conducted with 1 µg RNA using PrimeScript RT Master Mix kit (Takara, Japan). Then, quantitative PCR (qPCR) was carried out in StepOnePlusTM Real-Time PCR Instrument (Thermo Fisher Scientific) using the TB Green Premix Ex Taq II kit (Takara, Japan). The relative mRNA expression levels were calculated using β-Action as the internal control. All primer sequences are listed in Additional file 5: Table S1.
MeRIP-seq and MeRIP-qPCR
The m6A MeRIP-seq and MeRIP-qPCR were performed according to the published procedures with slight modifications [29, 34]. Briefly, total RNA was fragmented with ZnCl2 and incubated with anti-m6A polyclonal antibody (Synaptic Systems, 202,003) or anti-IgG antibody (Abcam, ab150080) for 2 h at 4 °C. Then above RNA was incubated with protein A/G magnetic beads (Thermo Fisher Scientific; 88,802) for 2 h at 4 °C to obtain immunoprecipitated RNA fragments. The bound RNA was purified for sequencing library construction and qRT-PCR. The library was sequenced with the Illumina Next-Seq 500 sequencer and analyzed as previously described. Methylated sites on RNAs (peaks) were identified with MACS software.
RNA m 6 A dot blot assays
After denaturing at 95 °C for 3 min, 2 μg of total RNA was crosslinked twice to the Hybond-N + membrane using a crosslinker with 1,200 μJ for 50 s. The membrane was incubated with m6A antibody, followed by secondary antibody. The dot blot signal intensity was detected by ECL with Tanon 5200 Multi intelligent imaging system. Then the membrane was stained with 0.02% Methylene blue (Sigma-Aldrich, St. Louis, USA) and scanned to reveal total input RNA content.
RNA and protein stability assays
To assess the RNA and protein stability, RNA and protein decay assays were conducted. For RNA decay assay, OSCC cells were treated with actinomycin D (ActD, 5 μg/mL) for 0, 3, and 6 h. Total RNA was then isolated and the relative abundance of FGFR3 mRNA (relative to 0 h) was quantified using qRT-PCR. For protein decay assay, OSCC cells were treated with cycloheximide (CHX, 100 μg/mL) (Sigma-Aldrich) at 0, 2, 4, and 8 h. Then the expression of FGFR3 was detected via western blotting.
Patient-derived tumor xenograft (PDX) models and immunohistochemistry staining (IHC)
The OSCC PDX models were established as previously described . In brief, eight patients’ samples were used to establish the PDX models and the PDX mice were treated with 3 mg/kg anlotinib or normal saline (oral administration, once a day). The tumor growth inhibition (TGI) rate was calculated as (1-(Tn-T0)/(Cn-C0)) × 100% and presented in our previous study .
Tissue slides from PDX models were routinely deparaffinized and rehydrated. Following endogenous peroxidase quenching and antigen retrieval, the slides were blocked with 5% BSA for 30 min, followed by incubation with primary antibodies against METTL3 (Proteintech, 15,073–1-AP), FGFR3 (Signalway Antibody, 33,373) and p-FGFR3 (Affinity Biosciences, AF8439) overnight at 4℃. Then secondary antibodies and SABC were applied with SABC-POD (rabbit IgG) kit (BOSTER, Wuhan, China). The slides were stained using 3, 3’-diaminobenzidine (DAB) kit (BOSTER) and then counterstained with hematoxylin.
The data were presented as the mean ± standard deviation (SD). Differences between the two groups were determined using the student’s t-tests. Statistical analyses were carried out using SPSS (version 25.0; IBM Corporation, Armonk, NY, USA). P < 0.05 were considered statistically significant. All experiments were performed in triplicate.
Anlotinib targets FGFR3 and inhibits FGFR3 phosphorylation in the treatment of OSCC
To explore the possible anlotinib targets, firstly, we detected the mRNA expression levels of VEGFR1-3, FGFR1-4, PDGFRβ and C-KIT genes in four OSCC cell lines by qRT-PCR. We found that HUVECs mainly expressed FGFR1 and VEGFR2 mRNA (Fig. 1A and Table 1). However, HOK and OSCC cells expressed low mRNA levels of VEGFR1-3, PDGFRβ and C-KIT genes, but with high mRNA levels of FGFR1-4 genes (Fig. 1A and Table 1). Furthermore, four OSCC cell lines mainly expressed FGFR3 mRNA among FGFR1-4 (Fig. 1A and Table 1). We further evaluated the protein levels of the above genes by western blotting and found that VEGFR1, c-Kit and PDGFRβ were barely detected, VEGFR2 and VEGFR3 protein were basically not expressed in OSCC cells (Fig. 1B). Meanwhile, FGFR3 protein had the highest expression levels among FGFR1-4 protein in OSCC cells (Fig. 1B). Although the FGFR3 protein levels were not obviously changed after anlotinib treatment, we discovered the phosphorylation levels of FGFR3 significantly reduced in the anlotinib group in a dose-dependent manner in OSCC cells comparing with the non-anlotinib group (Fig. 1C and Additional file 1: Fig. S1). These above results implied that FGFR3 may act as a target of anlotinib in OSCC cells.
FGFR3 expression level affects antitumor activity of anlotinib in OSCC
To further examine the role of FGFR3 in anlotinib-induced antitumor effects in OSCC, three different sequences of siFGFR3 were used to transfer into SCC9 and SCC15 cells, and the siRNA with the highest silencing efficacy (siFGFR3-3) was selected for subsequent experiments (Fig. 2A). As shown in Fig. 2B–D, anlotinib induced proliferation inhibition (Fig. 2B) and cellular apoptosis (Fig. 2C) in SCC9 and SCC25 in a dose-dependent manner. The phosphorylation of FGFR3, AKT and mTOR was decreased after anlotinib treatment (Fig. 2D). The ability of proliferation inhibition and apoptosis stimulation effects of anlotinib was significantly decreased after knockdown FGFR3 in OSCC cells, moreover, the phosphorylation levels of FGFR3, AKT and mTOR were slightly increased after knockdown FGFR3, suggesting that lower FGFR3 expression levels led to less anlotinib sensitivity of OSCC. Recombinant human FGF-2 (rhFGF-2, 20 ng/mL), which can stimulate autophosphorylation of FGFR3 and the phosphorylation levels of AKT and mTOR, also significantly diminished the ability of proliferation inhibition and apoptosis stimulation effects of anlotinib in OSCC cells (Fig. 2B, C and Additional file 2: Fig. S2). After anlotinib treatment, the phosphorylation levels of FGFR3, AKT and mTOR were decreased in rhFGF-2-treated plus anlotinib group. These changes caused subsequent corresponding changes of downstream apoptosis proteins, including BAX and BCL-2 (Fig. 2D).
Overall, these results suggested that anlotinib targeted and inhibited FGFR3 phosphorylation levels and then affected the subsequent AKT/mTOR phosphorylation to cause apoptosis of OSCC cells.
METTL3 regulates FGFR3 mRNA m 6 A modification and decreases FGFR3 mRNA stability
To investigate how METTL3 regulate FGFR3 in OSCC cells, firstly, we knocked down METTL3 in SCC9 and SCC25 cells and found that the m6A levels were significantly decreased in METTL3-knockdown group by dot-blot analysis (Fig. 3A). We then analyzed the data of m6A MeRIP-seq from our previous study  and found that the m6A peaks of FGFR3 were enriched near the 3’UTR regions (Fig. 3B). MeRIP-qPCR assay also showed that FGFR3 m6A modification was significantly decreased after METTL3 knockdown in SCC9 and SCC25 cells (Fig. 3C). Western blotting showed that METTL3 knockdown increased FGFR3 protein and mRNA expression levels, and also increased the FGFR3 phosphorylation levels (Fig. 3D). These data suggested that METTL3 might regulate FGFR3 expression at the post-transcriptional level.
Moreover, we compared FGFR3 mRNA and protein stability in METTL3-knockdown group with control cells by actinomycin D and cycloheximide assay. We determined that the stability of FGFR3 mRNA level was remarkably increased in METTL3-knockdown cells compared with control cells, but without changing the degradation rate of FGFR3 protein level (Fig. 3E, F). The results manifested that FGFR3 mRNA m6A modification by METTL3 could accelerate its degradation.
METTL3 are inversely associated with anlotinib sensitivity in OSCC cells
To investigate the role of METTL3 in anlotinib treated OSCC cells, we explored the correlation between anlotinib sensitivity (IC50 values) and METTL3 expression level in OSCC cell lines. Four OSCC cell lines (SCC9, SCC15, SCC25 and UM1) were treated with anlotinib (Fig. 4A), and the expression of endogenous METTL3 was assessed by qRT-PCR and western blotting in OSCC cell lines (Fig. 4B, C). Strong correlation between IC50 and METTL3 expression level was identified in OSCC cells. The OSCC cells with higher METTL3 expression were less sensitive to anlotinib (higher IC50 values) (Table 2). METTL3 knockdown in OSCC cells sensitized the inhibitory effects of anlotinib in OSCC cells. The IC50 value decreased and the cellular apoptosis increased after anlotinib treatment in METTL3 knockdown OSCC cells (Fig. 4D, E and Additional file 3: Fig. S3).
METTL3 affects the FGFR3 expression and antitumor efficacy of anlotinib in PDX models
To verify the relationship between METTL3, FGFR3 and antitumor sensitivity of anlotinib in vivo, we explored the expression level of METTL3 and FGFR3 of tumor tissues from eight previously established OSCC PDX models . After 30 days of anlotinib treatment, the TGI rate of anlotinib was evaluated to measure the antitumor sensitivity of anlotinib in OSCC PDX. TGI values in eight PDX models were 95.90 (#005), 92.28 (#010), 78.07 (#022), 92.85 (#024), 92.89 (#030), 92.89 (#032), 88.25 (#034) and 89.18% (#040). Histopathological examination (H&E) and IHC assay were used to detect the expression level of METTL3/FGFR3/p-FGFR3 in the control group of each PDX model (Fig. 5A–D). As shown in Fig. 5E, the expression level of METTL3/FGFR3 had significant correlation with TGI rate in PDX models. PDX models with the lower expression level of METTL3 or the higher expression level of FGFR3 displayed more sensitivity to anlotinib treatment with a higher TGI rate (Fig. 5E). Meanwhile, the expression levels of METTL3 and FGFR/p-FGFR3 were negatively correlated in each PDX sample significantly (Fig. 5E). Furthermore, we detected METTL3 and FGFR3 expression levels of 97 OSCC patients’ tissues by IHC, and the results verified that the expression levels of METTL3 and FGFR3 were negatively correlated significantly (Additional file 4: Fig. S4).
In recent decades, despite the application of various treatment modalities for OSCC, the five‐year overall survival rate of OSCC remains at 50% . As a new, orally administered multi-target TKI, anlotinib exhibits excellent antitumor effects for several types of cancer [12, 36,37,38]. Our previous study  also confirmed that anlotinib exerted potent antiproliferation capability and induced apoptosis in OSCC cells, and favorable anticancer activity and manageable toxicities in patients with recurrent and metastatic OSCC. Until now tremendous studies have been performed to investigate the mechanism of anlotinib in the treatment of human cancers. Previous studies have found that PI3K/AKT/ mTOR signaling pathway and downstream apoptosis pathway were typical mechanism in anlotinib treatment . Song et al.  found that anlotinib mainly inhibited the phosphorylation level of VEGFR2 and then affected PIK3/AKT signal activation in intrahepatic cholangiocarcinoma (ICC). Yang et al.  suggested that anlotinib suppressed cell proliferation and angiogenesis via inhibition of VEGFR-2/AKT and FGFR, PDGFRβ and their downstream signaling ERK in colorectal cancer. In this study, we further confirmed that the antitumor effect of anlotinib was conducted by targeting FGFR3 and inhibiting the phosphorylation level of FGFR3, and subsequent inhibition of the AKT/mTOR and apoptosis signaling pathway in OSCC. Taken together, these results suggested that anlotinib may be involved in the FGFR3/AKT/mTOR signaling pathway in the therapeutics of OSCC.
As the most pervasive internal modification of mRNA, m6A modification is installed by a methyltransferase complex (e.g., METTL3-METTL14), erased by demethylases (e.g., FTO and ALKBH5), and can be recognized by readers (e.g., YTHDF1-3, IGF2BP1-3) . Studies have proved that mRNA m6A modification can affect RNA splicing, RNA stability, RNA translation efficiency, RNA secondary structure and RNA subcellular localization . Tremendous studies have shown that METTL3 promotes tumor growth, metastasis, and drug resistance in human cancers [26,27,28, 40, 41]. Recently, Yan et al.  identified the dynamic m6A methylome as an additional epigenetic driver for reversible TKI tolerance. Ianniello et al.  also revealed that downregulation of METTL3 and METTL14 overcame the resistance of chronic myeloid leukemia cells to the TKI imatinib mesylate (imatinib) through regulating ribosome levels and translation. Sa et al.  demonstrated that insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2)-dependent ERBB2 signaling activation contributes to acquired resistance to TKI of radioiodine-refractory papillary thyroid cancer. In the present study, we observed the function of m6A methylation in regulating anlotinib sensitivity of OSCC, providing a mechanistic paradigm for drug sensitivity in cancer. Cell lost-of-functional assays revealed that FGFR3 act as the anlotinib target in OSCC cells. Our MeRIP-seq and MeRIP-qPCR results demonstrated that FGFR3 was selectively m6A modified in OSCC. Depletion of METTL3 decreased FGFR3 m6A methylation and mRNA stability, and promoted anlotinib sensitivity of OSCC cells. OSCC PDX models verified that METTL3 and FGFR3 levels were tightly correlated with the anlotinib efficacy in the treatment of OSCC, also the expression levels of METTL3 and FGFR were significantly negatively correlated in each PDX sample. Thus, METTL3-mediated m6A modification played a critical function in the anlotinib sensitivity of OSCC.
Anlotinib targeted and inhibited FGFR3 phosphorylation in the treatment of OSCC. METTL3 modified FGFR3 m6A methylation and decreased its stability which attenuated the effect of anlotinib. The METTL3/m6A axis could serve as a biomarker to predict response of the OSCC patients to the anlotinib treatment.
Availability of data and materials
All data generated or analyzed during this study are included in this article [and its additional files].
Oral squamous cell carcinoma
Patient-derived tumor xenograft
Tyrosine kinase inhibitor
Vascular endothelial cell growth factor receptor
Stem cell growth factor receptor
Platelet-derived growth factor receptor beta
Fibroblast growth factor receptor
B cell-specific Moloney murine leukemia virus insertion site 1
ATP binding cassette subfamily G member 2
Ubiquitin-conjugating enzyme E2B
M6A-RNA immunoprecipitation and sequencing
Human normal oral epithelial keratinocytes
Human umbilical cord veins cells
Fetal bovine serum
Small interfering RNA
Short hairpin RNA
Tumor growth inhibition
Chow LQM. Head and neck cancer. N Engl J Med. 2020. https://doi.org/10.1056/NEJMra1715715.
Pfister DG, Spencer S, Adelstein D, et al. Head and neck cancers, version 2.2020, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2020. https://doi.org/10.6004/jnccn.2020.0031.
Taberna M, Oliva M, Mesía R. Cetuximab-containing combinations in locally advanced and recurrent or metastatic head and neck squamous cell carcinoma. Front Oncol. 2019. https://doi.org/10.3389/fonc.2019.00383.
Ferris RL. Immunology and immunotherapy of head and neck cancer. J Clin Oncol. 2015. https://doi.org/10.1200/jco.2015.61.1509.
Micaily I, Johnson J, Argiris A. An update on angiogenesis targeting in head and neck squamous cell carcinoma. Cancers Head Neck. 2020. https://doi.org/10.1186/s41199-020-00051-9.
Cohen EEW, Bell RB, Bifulco CB, et al. The society for immunotherapy of cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC). J Immunother Cancer. 2019. https://doi.org/10.1186/s40425-019-0662-5.
Qiang W, Dai Y, Xing X, Sun X. Identification and validation of a prognostic signature and combination drug therapy for immunotherapy of head and neck squamous cell carcinoma. Comput Struct Biotechnol J. 2021. https://doi.org/10.1016/j.csbj.2021.01.046.
Patel B, Saba NF. Current aspects and future considerations of EGFR inhibition in locally advanced and recurrent metastatic squamous cell carcinoma of the head and neck. Cancers. 2021. https://doi.org/10.3390/cancers13143545.
Syed YY. Anlotinib: first global approval. Drugs. 2018. https://doi.org/10.1007/s40265-018-0939-x.
Shen G, Zheng F, Ren D, et al. Anlotinib: a novel multi-targeting tyrosine kinase inhibitor in clinical development. J Hematol Oncol. 2018. https://doi.org/10.1186/s13045-018-0664-7.
Xie C, Wan X, Quan H, et al. Preclinical characterization of anlotinib, a highly potent and selective vascular endothelial growth factor receptor-2 inhibitor. Cancer Sci. 2018. https://doi.org/10.1111/cas.13536.
Wang G, Sun M, Jiang Y, et al. Anlotinib, a novel small molecular tyrosine kinase inhibitor, suppresses growth and metastasis via dual blockade of VEGFR2 and MET in osteosarcoma. Int J Cancer. 2019. https://doi.org/10.1002/ijc.32180.
Song F, Hu B, Cheng JW, et al. Anlotinib suppresses tumor progression via blocking the VEGFR2/PI3K/AKT cascade in intrahepatic cholangiocarcinoma. Cell Death Dis. 2020. https://doi.org/10.1038/s41419-020-02749-7.
Lin B, Song X, Yang D, Bai D, Yao Y, Lu N. Anlotinib inhibits angiogenesis via suppressing the activation of VEGFR2, PDGFRβ and FGFR1. Gene. 2018. https://doi.org/10.1016/j.gene.2018.02.026.
Deng Z, Liao W, Wei W, et al. Anlotinib as a promising inhibitor on tumor growth of oral squamous cell carcinoma through cell apoptosis and mitotic catastrophe. Cancer Cell Int. 2021. https://doi.org/10.1186/s12935-020-01721-x.
Huang Z, Su Q, Li W, et al. Suppressed mitochondrial respiration via NOX5-mediated redox imbalance contributes to the antitumor activity of anlotinib in oral squamous cell carcinoma. J Genet Genomics. 2021. https://doi.org/10.1016/j.jgg.2021.06.014.
Lu J, Xu W, Qian J, et al. Transcriptome profiling analysis reveals that CXCL2 is involved in anlotinib resistance in human lung cancer cells. BMC Med Genom. 2019. https://doi.org/10.1186/s12920-019-0482-y.
Gu G, Hu C, Hui K, et al. NEAT 1 knockdown enhances the sensitivity of human non-small-cell lung cancer cells to anlotinib. Aging. 2021. https://doi.org/10.18632/aging.203004.
Vadlapatla RK, Vadlapudi AD, Pal D, et al. Mechanisms of drug resistance in cancer chemotherapy: coordinated role and regulation of efflux transporters and metabolizing enzymes. Curr Pharm Des. 2013. https://doi.org/10.2174/13816128113199990493.
Silva SN, Tomar M, Paulo C, et al. Breast cancer risk and common single nucleotide polymorphisms in homologous recombination DNA repair pathway genes XRCC2, XRCC3, NBS1 and RAD51. Cancer Epidemiol. 2010. https://doi.org/10.1016/j.canep.2009.11.002.
Wilting RH, Dannenberg JH. Dannenberg, epigenetic mechanisms in tumorigenesis, tumor cell heterogeneity and drug resistance. Drug Resist Updat. 2012. https://doi.org/10.1016/j.drup.2012.01.008.
Rueff J, Rodrigues AS. Cancer drug resistance: a brief overview from a genetic viewpoint. Methods Mol Biol. 2016. https://doi.org/10.1007/978-1-4939-3347-1_1.
Niu Y, Wan A, Lin Z, et al. N6-Methyladenosine modification: a novel pharmacological target for anti-cancer drug development. Acta Pharm Sin B. 2018. https://doi.org/10.1016/j.apsb.2018.06.001.
Cui Q, Shi H, Ye P, et al. m6A RNA methylation regulates the self-renewal and tumorigenesis of glioblastoma stem cells. Cell Rep. 2017. https://doi.org/10.1016/j.celrep.2017.02.059.
Liu J, Eckert MA, Harada BT, et al. m6A mRNA methylation regulates AKT activity to promote the proliferation and tumorigenicity of endometrial cancer. Nat Cell Biol. 2018. https://doi.org/10.1038/s41556-018-0174-4.
Lan Q, Liu PY, Bell JL, et al. The emerging roles of RNA m6A methylation and demethylation as critical regulators of tumorigenesis, drug sensitivity, and resistance. Cancer Res. 2021. https://doi.org/10.1158/0008-5472.can-20-4107.
Liu S, Li Q, Li G, et al. The mechanism of m6A methyltransferase METTL3-mediated autophagy in reversing gefitinib resistance in NSCLC cells by β-elemene. Cell Death Dis. 2020. https://doi.org/10.1038/s41419-020-03148-8.
Lin Z, Niu Y, Wan A, et al. RNA m6A methylation regulates sorafenib resistance in liver cancer through FOXO3-mediated autophagy. EMBO J. 2020. https://doi.org/10.15252/embj.2019103181.
Liu L, Wu Y, Li Q, et al. METTL3 Promotes Tumorigenesis and Metastasis through BMI1 m6A methylation in oral squamous cell carcinoma. Mol Ther. 2020. https://doi.org/10.1016/j.ymthe.2020.06.024.
Jin D, Guo J, Wu Y, et al. m6A mRNA methylation initiated by METTL3 directly promotes YAP translation and increases YAP activity by regulating the MALAT1-miR-1914-3p-YAP axis to induce NSCLC drug resistance and metastasis. J Hematol Oncol. 2019. https://doi.org/10.1186/s13045-019-0830-6.
Uddin MB, Roy KR, Hosain SB, et al. An N6-methyladenosine at the transited codon 273 of p53 pre-mRNA promotes the expression of R273H mutant protein and drug resistance of cancer cells. Biochem pharmacol. 2019. https://doi.org/10.1016/j.bcp.2018.12.014.
Narayanan S, Cai CY, Assaraf YG, et al. Targeting the ubiquitin-proteasome pathway to overcome anti-cancer drug resistance. Drug Resist Updat. 2020. https://doi.org/10.1016/j.drup.2019.100663.
Taketo K, Konno M, Asai A, et al. The epitranscriptome m6A writer METTL3 promotes chemo- and radioresistance in pancreatic cancer cells. Int J Oncol. 2018. https://doi.org/10.3892/ijo.2017.4219.
Dominissini D, Moshitch-Moshkovitz S, Salmon-Divon M, et al. Transcriptome-wide mapping of N6-methyladenosine by m6A-seq based on immunocapturing and massively parallel sequencing. Nat Protoc. 2013. https://doi.org/10.1038/nprot.2012.148.
Weckx A, Grochau KJ, Grandoch A, et al. Survival outcomes after surgical treatment of oral squamous cell carcinoma. Oral Dis. 2020. https://doi.org/10.1111/odi.13422.
Lu J, Zhong H, Chu T, et al. Role of anlotinib-induced CCL2 decrease in anti-angiogenesis and response prediction for nonsmall cell lung cancer therapy. Eur Respir J. 2019. https://doi.org/10.1183/13993003.01562-2018.
Chen XZ. Anlotinib for refractory advanced non-small cell lung Cancer in China. JAMA Oncol. 2019. https://doi.org/10.1001/jamaoncol.2018.5526.
Zhou AP, Bai Y, Song Y, et al. Anlotinib versus sunitinib as first-line treatment for metastatic renal cell carcinoma: a randomized phase II clinical trial. Oncologist. 2019. https://doi.org/10.1634/theoncologist.2018-0839.
Yang Q, Ni L, Imani S, et al. Anlotinib suppresses colorectal cancer proliferation and angiogenesis via inhibition of AKT/ERK signaling cascade. Cancer Manag Res. 2020. https://doi.org/10.2147/cmar.s252181.
Gao F, Wang Q, Zhang C, et al. RNA methyltransferase METTL3 induces intrinsic resistance to gefitinib by combining with MET to regulate PI3K/AKT pathway in lung adenocarcinoma. J Cell Mol Med. 2021. https://doi.org/10.1111/jcmm.16114.
Bi X, Lv X, Liu D, et al. METTL3-mediated maturation of miR-126-5p promotes ovarian cancer progression via PTEN-mediated PI3K/Akt/mTOR pathway. Cancer Gene Ther. 2021. https://doi.org/10.1038/s41417-020-00222-3.
Yan F, Al-Kali A, Zhang Z, He MR, Litzow SL, et al. A dynamic N6-methyladenosine methylome regulates intrinsic and acquired resistance to tyrosine kinase inhibitors. Cell Res. 2018. https://doi.org/10.1038/s41422-018-0097-4.
Ianniello Z, Sorci M, Ceci Ginistrelli L, et al. New insight into the catalytic-dependent and -independent roles of METTL3 in sustaining aberrant translation in chronic myeloid leukemia. Cell Death Dis. 2021. https://doi.org/10.1038/s41419-021-04169-7.
Sa R, Liang R, Qiu X, et al. IGF2BP2-dependent activation of ERBB2 signaling contributes to acquired resistance to tyrosine kinase inhibitor in differentiation therapy of radioiodine-refractory papillary thyroid cancer. Cancer Lett. 2021. https://doi.org/10.1016/j.canlet.2021.12.005.
This study was supported by National Natural Science Foundation of China (82173041 and 82002871).
Ethical approval and consent to participate.
The animal experiments were approved by the Ethical Committee of the First Affiliated Hospital, Sun Yat-Sen University (No.  069).
Consent for publication
The authors have declared that no conflict of interest exists.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Quantification of the expression and phosphorylation levels of FGFR3 after anlotinib treated in OSCC cells. (corresponded to Fig. 1C).
Representative images of cell apoptosis assays showed the ratio of apoptosis cells of anlotinib-treated (24h) in OSCC cells. (corresponded to Fig. 2C).
Representative images of cell apoptosis assays showed the ratio of apoptosis cells of anlotinib-treated (24h) after METTL3 knockdown in OSCC cells. (corresponded to Fig. 4E).
Representative images of IHC staining of METTL3 and FGFR3 of OSCC patients’ tissues, and the correlation between IHC score of METTL3 and FGFR3. (corresponded to Fig. 5).
The shRNA or siRNA sequence and primer sequence for RT-PCR.
About this article
Cite this article
Chen, J., Li, S., Huang, Z. et al. METTL3 suppresses anlotinib sensitivity by regulating m6A modification of FGFR3 in oral squamous cell carcinoma. Cancer Cell Int 22, 295 (2022). https://doi.org/10.1186/s12935-022-02715-7
- m6A methylation